Online inquiry

IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12598MR)

This product GTTS-WQ12598MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromboembolic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000128.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2160
UniProt ID P03951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12598MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13446MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ3704MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ4171MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ7353MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ1336MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ14181MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ4602MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ4548MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW